Galectin-3 is a Nanotherapeutic Target in Graft-versus-Host Disease Mediated Kidney Injury
Magdalini Panagiotakopoulou, Ashley N. Sullivan, Kimon V. Argyropoulos, Anastasia I. Kousa, Logan R. Hillger, Kaitlyn Pierpont, Jorge Nunez, Eric Rosiek, Francesca Mazzoni, Wenfei Kang, Emma Grabarnik, Anastasiya Egorova, Brianna Gipson, Romina Ghale, Stephen B. Ruiz, , Daniel A. Heller
The paper identifies galectin-3 as a target for nanotherapeutic delivery of ruxolitinib to reduce GVHD-related kidney injury and systemic inflammation.
bioRxiv · Nov 19, 2025 · PreprintBioengineering